Aura Biosciences (AURA)
(Delayed Data from NSDQ)
$8.58 USD
-0.33 (-3.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $8.59 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Income Statements
Fiscal Year end for Aura Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 60 | 35 | 22 | 0 |
Income After Depreciation & Amortization | -85 | -60 | -35 | -22 | 0 |
Non-Operating Income | 9 | 2 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -76 | -59 | -35 | -22 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -76 | -59 | -35 | -22 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -76 | -59 | -35 | -22 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -84 | -59 | -34 | -21 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | NA |
Income After Depreciation & Amortization | -85 | -60 | -35 | -22 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 39.62 | 29.94 | 5.16 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.93 | -1.96 | -8.95 | NA | NA |
Diluted Net EPS (GAAP) | -1.93 | -1.96 | -8.95 | NA | NA |
Fiscal Year end for Aura Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 22.76 | 22.31 | 24.78 | 20.49 | 20.28 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.76 | -22.31 | -24.78 | -20.49 | -20.28 |
Non-Operating Income | 2.43 | 2.65 | 2.58 | 1.98 | 1.98 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -20.34 | -19.66 | -21.99 | -18.51 | -18.30 |
Income Taxes | 0.00 | 0.05 | 0.14 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -20.34 | -19.71 | -22.13 | -18.51 | -18.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -20.34 | -19.71 | -22.13 | -18.51 | -18.30 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 49.55 | 49.45 | 44.44 | 38.19 | 37.86 |
Diluted EPS Before Non-Recurring Items | -0.41 | -0.40 | -0.50 | -0.48 | -0.48 |
Diluted Net EPS (GAAP) | -0.41 | -0.40 | -0.51 | -0.48 | -0.48 |